TechFlow_logo_AA.png
TechFlow Secures 7-Year $2.1 Billion TSA Contract for Explosives Detection System Upkeep at Over 300 Facilities Spanning the U.S. and its Territories
December 07, 2023 08:00 ET | TechFlow, Inc.
TechFlow Secures 7-Year $2.1 Billion TSA Contract for Explosives Detection System Upkeep at Over 300 Facilities Spanning the U.S. and its Territories
Axsome Logo.png
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 03, 2022 06:30 ET | Axsome Therapeutics, Inc.
Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint) Statistically significant patient-reported improvement in...
Axsome Logo.png
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research
September 07, 2022 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
June 28, 2022 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
June 22, 2022 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Logo.png
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
March 28, 2022 06:00 ET | Axsome Therapeutics, Inc.
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated...
AVX to Attend & Announce New Products at EDS 2015
April 28, 2015 13:22 ET | AVX Corporation
GREENVILLE, S.C., April 28, 2015 (GLOBE NEWSWIRE) -- AVX Corporation, a leading manufacturer of passive components and interconnect solutions, is attending the 2015 Electronic Distribution Show (EDS),...
avnet50yr
AVX & AVNET CELEBRATE 50 YEARS OF SUCCESS
August 05, 2013 16:51 ET | AVX Corporation
GREENVILLE, S.C., Aug. 5, 2013 (GLOBE NEWSWIRE) -- AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has become the first passive supplier to celebrate a...
Omron Electronic Components Announces 2012 Supplier Business Manager of the Year
June 03, 2012 23:46 ET | Omron Electronic Components, LLC
SCHAUMBURG, IL--(Marketwire - Jun 3, 2012) - Omron Electronic Components presented Mr. Jason Shaw of Arrow Electronics with the 2012 Supplier Business Management of the Year award at the annual...
Omron Presents 2012 Award to TTI for Their Superior Electromechanical Segment Focus
June 03, 2012 23:39 ET | Omron Electronic Components, LLC
SCHAUMBURG, IL--(Marketwire - Jun 3, 2012) - Omron Electronic Components LLC presented TTI with the 2012 Electromechanical Segment Focus Award, at the Electronics Distribution Show in Las Vegas....